07.12.21 — The Cell & Gene Talent Crunch, RNA-Engineered Cell Therapy, and Real-Time Clinical Analysis from the Business of Biotech Podcast

Check out the latest episodes from The Business of Biotech, Biotech with the Bozenhardts, and Life Science Connect. As a member of the Life Science Connect community, you have access to content beyond our weekly newsletters, including our podcast series. Don’t forget to subscribe so you never miss an episode!

BridgeBio has a whopping 30+ preclinical to clinical-stage candidates in its pipeline, representing a formidable array of modalities and targets. It boasts a pair of business wins underneath its belt. Central to its success are partnerships with scientists and researchers to gasoline pipeline growth. Here, BridgeBio CBO Michael Henderson, M.D., walks us by the components behind the firm’s academia-led progress technique.

Michael Mehler honed his cell remedy chops at Adaptimmune earlier than becoming a member of GSK as senior medical improvement supervisor, cell remedy oncology, in 2017. He and Cell & Gene chief editor Erin Harris joined the Business of Biotech podcast for a candid and detailed dialogue on discovering, hiring, and retaining cell and gene remedy professionals, facilitating their ongoing coaching, bridging the hole between academia and trade, why medical suggestions is an underappreciated supply of intelligence, and the sources obtainable to cell and gene builders to additional their “pipelines” of bench-level expertise.

Cartesian president and CEO Murat Kalayoglu, M.D., Ph.D., has led three of his firm’s six autoimmune, oncology, and respiratory candidates by Phase 1/2 medical trials, and two others are on the cusp of coming into Phase 1 this 12 months. With so many applications in and coming into the clinic, he is an amazing alternative for a dialog on GMP expectations for Phase 1 first-in-human trials. Glean perception from Cartesian’s expertise and study the firm’s novel method to RNA-engineered cell therapies for oncology and past.

Glympse Bio president and CEO Dr. Caroline Loew explores the potentialities and implications of the in-vivo, bioengineered, tunable sensors the firm is growing for diagnostic and prognostic functions in protease-mediates ailments. Currently in the clinic with purposes for non-alcoholic steatohepatitis and different fibrotic ailments, in addition to non-small cell lung most cancers and different strong tumors, Glympse is unlocking an unprecedented view of near-real-time therapeutic response and therapeutic efficacy that might have huge implications on the method biologics are developed, refined, and studied in the clinic.

Herman and Erich Bozenhardt have a combined 55 years of bioprocess facilities design and equipment experience, and they’re here to share it all in our fresh Bioprocess with the Bozenhardts podcast collection.

According to Outsourced Pharma chief editor, Louis Garguilo, “Politics has by no means performed a much bigger function in our (international) biopharma trade.” In this episode, we discuss with Louis about three of his latest editorials that contact on this topic whereas additionally discussing the present IP debate in pharma and the origins of the coronavirus.

Three biopharmaceutical trade VPs of HR departments talk about the challenges of continued operations amidst COVID-19 initiated lockdowns, together with some of the greatest practices applied.

Fundraising used to at all times be accomplished in individual. But then COVID-19 hit. From these first digital pitches that will have been just a bit bit “wonky,” biopharma execs have really turn out to be fairly proficient at the course of and the platforms. Three biopharma execs share some greatest practices of the digital pitch.

Considering many Life Science Leader readers daydream of beginning and main their very own biopharmaceutical firm sometime, we thought it might be informative to host an government digital roundtable with three biopharmaceutical firm CEOs who’ve accomplished simply that.